Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

High Fusion Inc. (SPLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0200+0.0010 (+5.26%)
At close: 11:15AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0190
Open0.0125
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0125 - 0.0200
52 Week Range0.0100 - 0.3110
Volume64,773
Avg. Volume34,044
Market Cap2.829M
Beta (5Y Monthly)1.03
PE Ratio (TTM)0.15
EPS (TTM)0.1300
Earnings DateSep 30, 2022 - Oct 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SPLIF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HIGH FUSION INC
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    6 hours agoMorningstar
View more
  • Newsfile

    High Fusion Inc. Announces Amendment to Debentures

    Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") is pleased to announce an extension of the term of the August 2018 senior secured debentures ("Debentures") from August 3, 2022 to February 3, 2023.With the extension of the maturity date of the Debentures, the interest on the debentures to maturity will increase to 24% per annum. One half of the interest on the Debentures shall ...

  • Newsfile

    High Fusion Inc. Announces Change of Auditor

    Toronto, Ontario--(Newsfile Corp. - July 21, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") announces that it has changed its auditors from Harbourside CPA LLP (the "Former Auditor") to BF Borgers CPA PC (the "Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective July 14, 2021. The Company has appointed the Successor Auditor on July 18, 2021, until the next annual shareholders' meeting of the ...

  • Newsfile

    High Fusion Inc. Announces Financial Results for the Third Quarter Ending April 30, 2022

    Toronto, Ontario--(Newsfile Corp. - July 4, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") is pleased to announce its financial results for the third quarter ended April 30, 2022.Third Quarter HighlightsDuring the third quarter and nine-month period ended April 30, 2022, the Company achieved sales of $1,294,792 and $4,668,401 respectively compared with $50,753 during the corresponding periods of 2021. This increase was due to the inclusion of the business ...

Advertisement
Advertisement